Paglalarawan

The multi-drug resistance (MDR) antibiotics market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) ng mga 9.7% sa panahon ng pagtataya, ayon sa data at analytics company na StrategyHelix.

Ang ulat ay nagbibigay ng napapanahong data ng laki ng merkado para sa panahon 2017-2020 at forecast na 2027 covering key market aspects like sales value for multi-drug resistance (MDR) antibiotics. The China multi-drug resistance (MDR) antibiotics market is segmented on the basis of type. Ayon sa uri, it is categorized into daptomycin, linezolid, teicoplanin, and tigecycline.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd..

Ang ulat ay isang napakahalagang mapagkukunan para sa mga kumpanya at organisasyon na aktibo sa industriyang ito. It provides a cohesive picture of the multi-drug resistance (MDR) antibiotics market to help drive informed decision making for industry executives, mga gumagawa ng patakaran, akademiko, at mga analyst.

Saklaw ng Ulat

Uri ng: daptomycin, linezolid, teicoplanin, and tigecycline
Mga Taon na Itinuturing: Ang ulat na ito ay sumasaklaw sa panahon 2017 sa 2027

Mga Pangunahing Benepisyo para sa mga Stakeholder

Get a comprehensive picture of the China multi-drug resistance (MDR) antibiotics market
Pinpoint ang mga sektor ng paglago at mga trend para sa pamumuhunan
Understand what the future of the multi-drug resistance (MDR) antibiotics market in China looks like
Kilalanin ang mapagkumpitensya na landscape at window ng pagkakataon

Talaan ng mga Nilalaman

1. Kahulugan ng Market
2. Metodolohiya ng Pananaliksik
3. Market Data & Outlook
3.1 Halaga ng Market
3.2 Pagtataya ng Halaga sa Market
4. Multi-Drug Resistance (MDR) Antibiotics Market by Type
4.1 Daptomycin
4.2 Linezolid
4.3 Teicoplanin
4.4 Tigecycline
5. Mga Profile ng Kumpanya
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
5.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
5.3 North China Pharmaceutical Company Ltd.
5.4 Pfizer, Inc.
5.5 Zhejiang Hisun Pharmaceutical Co., Ltd.
5.6 Zhejiang Medicine Co., Ltd.
6. Apendiks
6.1 Tungkol sa StrategyHelix
6.2 Pagtanggi